Other

Shanghai Kanda Biotechnology Co, Ltd.

Shanghai Celgen Bio-pharmaceutical Co., Ltd.

Zeling Cai

Yi Chen

Heng Wu

Guobo Fang

Provided is an antibody-tumor necrosis factor α fusion protein and its preparation and applications. Specifically, the present disclosure relates to a fusion protein comprising an antibody moiety and a TNFα moiety, a nucleic acid molecule encoding same, a nucleic acid construct, a host cell and a method of production thereof, as well as applications of these materials in prevention and/or treatment of tumors.

Antibody-TNF α fusion protein and its preparation and applications

Human antibodies which specifically bind to human CTLA-4, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

CTLA-4 antibodies and uses thereof

A bispecific coupled antibody, a preparation method and an application thereof are provided. Specifically, an anti-CTLA-4 humanized single-chain antibody fragment (scFv) is provided, which has the advantages of high affinity and strong specificity. Using the anti-CTLA-4 antibody to construct a recombinant bispecific conjugated antibody (fusing a humanized anti-Her-2 full antibody (Trastuzumab) with anti-CTLA-4 human single-chain antibody (scFv, single-chain antibody fragment)) is capable of significantly enhancing the body's immune response and maintaining or enhancing the activation state of T cells.

Bispecific coupled antibody, preparation method and application thereof

The present invention provides a fusion protein inhibiting TACI-BAFF complex formation and preparation method therefor and use thereof. Specifically, the fusion protein of the present invention is of high biological activity for blocking BAFF/APPRIL, and may significantly lower the serum IgM concentration in normal Balb/c mice as well as the serum IgM and IgE concentration in C57/B6 mice with asthma. The TACI-Fc fusion protein of the present invention may be used in the treatment of autoimmune diseases, including asthma, systemic lupus eythematosus and rheumatoid arthritis, etc., and may also be used in the treatment of B cell enrichment-related diseases, including multiple myeloma, chronic lymphocytic leukemia, macroglobulinemia and plasmacytic leukemia, etc.

Growing community of inventors

Shanghai, China

Zeling Cai